DULUTH, GA, and RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- May 15, 2007 -- Merial Limited and SCYNEXIS, Inc. announced today that they have expanded the scope of their research collaboration as a result of the success of their first agreement which began in 2005. SCYNEXIS, a primary drug discovery and development company and collaborator with Merial, will, under the terms of a new multi-year agreement, significantly increase the capacity of their technologically advanced biological screening, bioanalytical, ADMET and medicinal chemistry efforts directed towards Merial projects.
